Please assess the completion status of the following clinical trial:

Trial Title: Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects may be included in the study if they meet all of the following inclusion criteria:~1. Males or females ≥18 years old~2. Diagnosis of ABSSSI suspected or confirmed to be caused by a Gram-positive pathogen requiring at least 5 days of IV therapy~3. An ABSSSI includes one of the following infections Wound infections, Cellulitis/erysipelas, Major cutaneous abscess~4. ABSSSI must present with at least 2 signs and symptoms~5. Able to give informed consent and willing to comply with all required study procedures~Exclusion Criteria:~Subjects will be excluded from the study if any of the following exclusion criteria apply prior to randomization:~1. Prior systemic or topical antibacterial therapy with activity against suspected or proven Gram-positive pathogens within the preceding 14 days~   * The causative Gram-positive pathogen(s) isolated from the ABSSSI site is resistant in vitro to the antibacterial(s) that was administered with documented clinical progression, or~  * Documented failure to previous ABSSSI antibiotic therapy is available. Documentation of treatment failure must be recorded~  * Patient received a single dose of a short acting antibacterial therapy three or more days before randomization~2. Infections associated with, or in close proximity to, a prosthetic device~3. Severe sepsis or refractory shock~4. Known or suspected bacteremia at time of screening~5. ABSSSI due to or associated with any of the following:~   * Infections suspected or documented to be caused by Gram-negative pathogens -- Wound infections (surgical or traumatic) and abscesses with only Gram-negative pathogens~  * Diabetic foot infections~  * Concomitant infection at another site not including a secondary ABSSSI lesion~  * Infected burns~  * A primary infection secondary to a pre-existing skin disease with associated inflammatory changes~  * Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease~  * Any evolving necrotizing process gangrene or infection suspected or proven to be caused by Clostridium species~  * Infections known to be caused by a Gram-positive organism with a vancomycin MIC \>2 μg/mL or clinically failing prior therapy with glycopeptides~  * Catheter site infections~6. Allergy or intolerance to aztreonam or metronidazole in a patient with suspected or proven polymicrobial wound infection involving Gram-negative and/or anaerobic bacteria~7. Currently receiving chronic systemic immunosuppressive therapy~8. AIDS with CD4 count \< 200 cells/mm3~9. Neutropenia~10. Significant or life-threatening condition that would confound or interfere with the assessment of the ABSSSI~11. Women who are pregnant or nursing~12. History of immune-related hypersensitivity reaction to glycopeptides~13. Patients that require anticoagulant monitoring with an aPTT~14. Contraindication to vancomycin~15. Patients unwilling to forego blood and/or blood product donation~16. Treatment with investigational medicinal product within 30 days before enrollment and for the duration of the study~17. Investigational device present, or removed \<30 days before enrollment, or presence of device-related infection~18. Patients unlikely to adhere to the protocol, comply with study drug administration, or complete the clinical study~19. Severe hepatic disease~20. Presence of hyperuricemia~21. Unwilling to refrain from chronic use of any medication with antipyretic properties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-Dose IV Oritavancin Diphosphate (Type: EXPERIMENTAL): None
- IV Vancomycin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).